The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.

In this podcast, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, and Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, discuss key updates in myelodysplastic syndromes (MDS) presented at this year’s meeting. Topics covered include the treatment of lower-risk and higher-risk disease, novel classification systems, clinical trial updates, and treatment options after failure to hypomethylating agents (HMAs).

The post Highlights in MDS at ASH 2022: treating lower-risk & higher-risk disease, trial updates, & more appeared first on VJHemOnc.

NH #644: Nat’l Monument Loophole Still Allows Grand Canyon Uranium Mining! Leona Morgan of Haul No